These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Optimising the design of phase II oncology trials: the importance of randomisation. Ratain MJ; Sargent DJ Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773 [TBL] [Abstract][Full Text] [Related]
27. Sorafenib for the treatment of advanced renal cell carcinoma. Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398 [TBL] [Abstract][Full Text] [Related]
28. Creeping phase II-ism and the medical pharmaceutical complex: weapons of mass distraction in the war against lung cancer. Turrisi AT J Clin Oncol; 2005 Aug; 23(22):4827-9. PubMed ID: 15939926 [No Abstract] [Full Text] [Related]
29. Development of growth inhibitory agents in urological and other malignancies. Stadler WM BJU Int; 2006 Sep; 98(3):497-502. PubMed ID: 16827906 [No Abstract] [Full Text] [Related]
30. Newer phase II trial designs gaining ground. Benowitz S J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467 [No Abstract] [Full Text] [Related]
32. Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance? Edelman MJ Expert Rev Anticancer Ther; 2003 Apr; 3(2):127-9. PubMed ID: 12722869 [No Abstract] [Full Text] [Related]
33. Molecule of the month. Sorafenib. Drug News Perspect; 2006 Mar; 19(2):119. PubMed ID: 16628266 [No Abstract] [Full Text] [Related]
34. Sorafenib: delivering a targeted drug to the right targets. Flaherty KT Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926 [TBL] [Abstract][Full Text] [Related]
35. New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS. Estey EH Ann Hematol; 2004; 83 Suppl 1():S94-6. PubMed ID: 15124692 [No Abstract] [Full Text] [Related]
36. Optimizing randomized phase II trials assessing tumor progression. Stone A; Wheeler C; Carroll K; Barge A Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129 [TBL] [Abstract][Full Text] [Related]
37. Improved confidence intervals for a binomial parameter following a group sequential phase II clinical trial. Chang MN Stat Med; 2004 Sep; 23(18):2817-26. PubMed ID: 15344188 [TBL] [Abstract][Full Text] [Related]
38. [The sensitivity of human kidney cancer in cultures to antitumor preparations]. Terent'eva TG; Fomina IP; Navashin SM; Martochkina GA Vopr Onkol; 1971; 17(7):67-70. PubMed ID: 5002944 [No Abstract] [Full Text] [Related]